Robert Lorne Hopfner, Director at Inozyme Pharma, Inc. (INZY), bought 415,680 shares at $3.70 ($1.7M) on 2023-03-27, disclosed to the SEC on 2023-03-29.
Open-market purchase of $1.7M INZY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.70 | 51,074 | $189K | 11.2% |
| 2 | $3.70 | 51,074 | $189K | 11.2% |
| 3 | $4.16 | 156,766 | $652K | 38.8% |
| 4 | $4.16 | 156,766 | $652K | 38.8% |
| Total | $4.05 avg | 415,680 | $1.7M | 100% |
| Filing → |
| INZY | BUY | 2023-05-15 | $5.7M | — | Filing → |
| INZY | BUY | 2023-03-30 | $3.1M | — | Filing → |
| INZY | BUY | 2022-04-20 | $3.9M | — | Filing → |